Which role for EGFR therapy in breast cancer

Vito Lorusso, Rosachiara Forcignano, Saverio Cinieri, Andrea Tinelli, Letizia Porcelli, Anna Elisa Quatrale, Vincenzo Emanuele Chiuri

Research output: Contribution to journalArticlepeer-review


EGFR and HER2 are highly expressed in 15-30% of breast cancer tissues. Therefore, EGFR and its downstream signaling pathways are promising anti-tumour targets. HER2 overexpression is often associated with estrogen receptor (ER) and progesterone receptor (PR) negativity, high histological grade, high rates of cell proliferation and lymph node involvement. Moreover, it is correlated with disease aggressiveness, increased rates of recurrence and poorer survival in node-positive breast cancer patients, whereas the prognostic significance in patients with node-negative tumors remains somewhat controversial. This paper focuses on the therapeutic strategy for treatment of HER2 overexpressing breast cancer in advanced stages of disease, as well as in the adjuvant and neo-adjuvant settings.

Original languageEnglish
Pages (from-to)31-42
Number of pages12
JournalFrontiers in Bioscience - Scholar
Volume4 S
Issue number1
Publication statusPublished - Jan 1 2012


  • Breast cancer
  • Egfr
  • Her2
  • Lapatinib
  • Review
  • Targeted therapy
  • Tirosine-kynase
  • Trastuzumab

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)


Dive into the research topics of 'Which role for EGFR therapy in breast cancer'. Together they form a unique fingerprint.

Cite this